|Articles|February 2, 2017

2016 Year in Review: University of Michigan V-BID Center

The University of Michigan Center for Value-Based Insurance Design (V-BID) celebrated significant initiative milestones in 2016.

Last year was a big year for value-based insurance design (VBID) and the University of Michigan Center for Value-Based Insurance Design celebrated significant initiative milestones in 2016. From the expansion of the Medicare Advantage VBID program, to the introduction of VBID in China, and the inclusion of a VBID demo in TRICARE, Center initiatives advanced markedly this year.

View the interactive timeline below for more on 2016 V-BID Center accomplishments, and keep up with the latest VBID news by following the Center on Twitter at @UM_VBID.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

2016 Year in Review: University of Michigan V-BID Center

Related Content

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Global HepB3 Coverage Reaches 81.8%, but Regional Gaps Persist

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

Gaps Persist in Interstitial Lung Disease Care

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

2016 Year in Review: University of Michigan V-BID Center

Related Content

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Global HepB3 Coverage Reaches 81.8%, but Regional Gaps Persist

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

Gaps Persist in Interstitial Lung Disease Care

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial